Promising predictors of transformation of endometrial hyperplasia

• Tatyana A. Gromova
• Sergey A. Levakov
• Nataliya A. Sheshukova
• Viktoriya V. Zolotareva

Abstract

Endometrial hyperplasia is a multifactorial disease and is considered one of the most common pathologies of the mucous membrane of the uterine body. The urgency of this problem is increasing from the standpoint of both the prevention of endometrial cancer and the restoration and preservation of reproductive function. There are currently no specific non-invasive diagnostic markers that allow assessing the prognosis of the progression and transformation of endometrial hyperplasia. This review considers relevant molecular genetic, immunohistochemical markers, and also considers the field of proteomics as potential predictors for risk stratification of endometrial hyperplasia transformation, potentially allowing to predetermine a treatment strategy and a personalized approach in each case. The significance of further studies is determined, which will allow the formation of a potentially new panel of non-invasive diagnostic markers of the transformation of this disease.

Keywords:endometrial hyperplasia; markers; endometrial transformation; endometrial cancer

REFERENCES

1. Clinical recommendations. hyperplasia of the endometrium. Version (07.01.2021). Moscow: Ministry of Health of the Russian Federation, 2021. URL: https://cr.minzdrav.gov.ru/schema/646_1 (in Russian)

2. Nees L.K., Heublein S., Steinmacher S., et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022; 306 (2): 407–21. DOI: https://doi.org/10.1007/s00404-021-06380-5

3. Chandra V., Kim J.J., Benbrook D.M., et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (l): 8. DOI: https://doi.org/10.3802/jgo.2016.27.e8

4. Kadirogullari R., Atalay C.R., Ozdemir O., Sari E.M. Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J Clin Diagn Res. 2015; 9 (10): 10–4. DOI: https://doi.org/10.7860/JCDR/2015/12484.6618

5. Travaglino A., Raffone A., Saccone G., et al. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019; 74 (5): 676–87. DOI: https://doi.org/10.1111/his.13776

6. Ordi J., Bergeron C., Hardisson D., et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology. 2014; 64 (2): 284–92. DOI: https://doi.org/10.1111/his.12249

7. Ring K.L., Mills A.M., Modesitt S.C. Endometrial hyperplasia. Obstet Gynecol. 2022; 140 (6): 1061–75. DOI: https://doi.org/10.1097/AOG.0000000000004989

8. Emons G., Beckmann M.W., Schmidt D., Mallmann P.; Uterus Commission of the Gynecological Oncology Working Group (AGO). New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015; 75 (2): 135–6. DOI: https://doi.org/10.1055/s-0034-1396256

9. Tzortzatos G., Andersson E., Soller M., et al. The gynecological surveillance of women with Lynch syndrome in Sweden. Gynecol Oncol. 2015; 138 (3): 717–22. DOI: https://doi.org/10.1016/j.ygyno.2015.07.016

10. van der Meer A.C., Hanna L.S. Development of endometrioid adenocarcinoma despite levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clin Obes. 2017; 7 (1): 54–7. DOI: https://doi.org/10.1111/cob.12168

11. Gao C., Wang Y., Broaddus R., et al. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget. 2018; 9: 5492–508. DOI: https://doi.org/10.18632/oncotarget.23695

12. Rosen M.W., Tasset J., Kobernik E.K., et al. Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger. J Pediatr Adolesc Gynecol. 2019; 32 (5): 546–9. DOI: https://doi.org/10.1016/j.jpag.2019.06.004

13. Wise M.R., Gill P., Lensen S., et al. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women. Am J Obstet Gynecol. 2016; 215 (5): 591–8. DOI: https://doi.org/10.1016/j.ajog.2016.06.006

14. Committee Opinion No. 601: tamoxifen and uterine cancer. Obstet Gynecol. 2014; 123 (6): 1394–7. DOI: https://doi.org/10.1097/01.AOG.0000450757.18294.cf

15. Lancaster J.M., Powell C.B., Chen L.M., Richardson D.L.; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015; 136 (1): 3–7. DOI: https://doi.org/10.1016/j.ygyno.2014.09.009

16. Colombo N., Creutzberg C., Amant F., et al.; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016; 26 (1): 2–30. DOI: https://doi.org/10.1097/IGC.0000000000000609

17. Ryan N.A.J., McMahon R., Tobi S., et al. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study. PLoS Med. 2020; 17 (9): e1003263. DOI: https://doi.org/10.1371/journal.pmed.1003263

18. Ghoubara A., Price M.J., Fahmy M.S.E., et al. Prevalence of hyperplasia and cancer in endometrial polyps in women with postmenopausal bleeding: a systematic review and meta-analysis. Post Reprod Health. 2019; 25 (2): 86–94. DOI: https://doi.org/10.1177/2053369119833583

19. Chen H., Strickland A.L., Castrillon D.H. Histopathologic diagnosis of endometrial precancers: updates and future directions. Semin Diagn Pathol. 2022; 39 (3): 137–47. DOI: https://doi.org/10.1053/j.semdp.2021.12.001

20. Aguilar M., Zhang H., Zhang M., et al. Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. J Pathol. 2021; 254: 20–30. DOI: https://doi.org/10.1002/path.5628

21. Strickland A.L., Rivera G., Lucas E., et al. PI3K Pathway effectors pAKT and FOXO1 as novel markers of endometrioid intraepithelial neoplasia. Int J Gynecol Pathol. 2019; 38: 503–13. DOI: https://doi.org/10.1097/PGP.0000000000000549

22. Raffone A., Travaglino A., Saccone G., et al. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: a systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand. 2019; 98: 287–99. DOI: https://doi.org/10.1111/aogs.13512

23. Costigan D.C., Dong F., Nucci M.R., Howitt B.E. Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol. 2020; 39: 119–27. DOI: https://doi.org/10.1097/PGP.0000000000000583

24. Kim G., Kurnit K.C., Djordjevic B., et al. Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018; 31: 1553–9. DOI: https://doi.org/10.1038/s41379-018-0080-0

25. Wright M.F., Fitzlaff S., Wyeth A., et al. Nuclear beta-catenin expression in endometrioid intraepithelial neoplasia (atypical hyperplasia) does not predict carcinoma on subsequent hysterectomy. Int J Gynecol Pathol. 2021; 40: 240–7. DOI: https://doi.org/10.1097/PGP.0000000000000695

26. Aguilar M., Chen H., Rivera-Colon G., et al. Reliable identification of endometrial precancers through combined Pax2, beta-catenin, and Pten immunohistochemistry. Am J Surg Pathol. 2022; 46 (3): 404–14. DOI: https://doi.org/10.1097/PAS.0000000000001810

27. Raffone A., Travaglino A., Saccone G., et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019; 127: 597–606. DOI: https://doi.org/10.1111/apm.12977

28. Ayhan A., Mao T.L., Suryo Rahmanto Y., et al. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. J Pathol Clin Res. 2015; 1 (3): 186–93. DOI: https://doi.org/10.1002/cjp2.22

29. Ponomarenko I.V., Polonikov A.V., Churnosov M.I. Association of ESR2 gene RS4986938 polymorphism with the development of endometrial hyperplasia. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2019; (4): 66–72. DOI: https://doi.org/10.18565/aig.2019.4.66-72 (in Russian)

30. Zaino R.J., Brady W.E., Todd W., et al. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014; 33: 543–53. DOI: https://doi.org/10.1097/PGP.0000000000000177

31. Chen H., Lucas E., Strickland A.L., et al. Specific biomarker expression patterns in the diagnosis of residual and recurrent endometrial precancers after progestin treatment: a longitudinal study. Am J Surg Pathol. 2020; 44: 1429–39. DOI: https://doi.org/10.1097/PAS.0000000000001537

32. Chatzipantelis P., Koukourakis M., Balaska K., Giatromanolaki A. Endometrial stromal expression of ER, PR, and B-catenin toward differentiating hyperplasia diagnoses. Int J Surg Pathol. 2022; 30 (5): 492–8. DOI: https://doi.org/10.1177/10668969211065110

33. Hiruma S., Kamasaki T., Otomo K., et al. Dynamics and function of ERM proteins during cytokinesis in human cells. FEBS Lett. 2017; 591 (20): 3296–309. DOI: https://doi.org/10.1002/1873-3468.12844

34. Agacayak E., Keles A., Deger U., et al. Could moesin be a new marker for indicating progression in endometrial cancer? Cancer Manag Res. 2022; 24 (14): 1247–57. DOI: https://doi.org/10.2147/CMAR.S353225

35. Cuylen S., Blaukopf C., Politi A.Z., et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 2016; 535 (7611): 308–12. DOI: https://doi.org/10.1038/nature18610

36. Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015; 11 (3): 1566–72. DOI: https://doi.org/10.3892/mmr.2014.2914

37. Ghalib Farhood R., Abd Ali Al-Humairi I. Immunohistochemical study of Ki-67 in hyperplastic and endometrium carcinoma: a comparative study. Arch Razi Inst. 2022; 77 (1): 229–34. DOI: https://doi.org/10.22092/ARI.2021.356540.1865

38. Hassan W.A., Ibrahim R. Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma. Int J Clin Exp Pathol. 2020; 13 (8): 2115–22.

39. Hayes J., Peruzzi P.P., Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20: 460–9. DOI: https://doi.org/10.1016/j.molmed.2014.06.005

40. Jayaraman M., Radhakrishnan R., Mathews C.A., et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes Cancer. 2017; 8: 566–76. DOI: https://doi.org/10.18632/genesandcancer.144

41. Giglio S., Annibali V., Cirombella R., et al. miRNAs as candidate biomarker for the accurate detection of atypical endometrial hyperplasia/endometrial intraepithelial neoplasia. Front Oncol. 2019; 21 (9): 526. DOI: https://doi.org/10.3389/fonc.2019.00526

42. Principe D.R., Doll J.A., Bauer J., et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014; 106 (2): 369. DOI: https://doi.org/10.1093/jnci/djt369

43. Shruthi B.S., Vinodhkumar P. Proteomics: a new perspective for cancer. Adv Biomed Res. 2016; 19 (5): 67. DOI: https://doi.org/10.4103/2277-9175.180636

44. Muinelo-Romay L., Casas-Arozamena C., Abal M. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. Int J Mol Sci. 2018; 19 (8): 2311. DOI: https://doi.org/10.3390/ijms19082311

45. Akkour K., Alanazi I.O., Alfadda A.A. Tissue-based proteomic profiling in patients with hyperplasia and endometrial cancer. Cells. 2022; 11 (13): 2119. DOI: https://doi.org/10.3390/cells11132119

46. Yamane T., Asanoma K., Kobayashi H., et al. Identification of the critical site of calponin 1 for suppression of ovarian cancer properties. Anticancer Res. 2015; 35: 5993–9.

47. Liu H., Li D., Zhou L., et al. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability. J Cell Mol Med. 2020; 24: 12 008–19. DOI: https://doi.org/10.1111/jcmm.15829

48. Cicchillitti L., Corrado G., Carosi M., et al. Prognostic role of NF-YA splicing isoforms and lamin A status in low grade endometrial cancer. Oncotarget. 2016; 8 (5): 7935–45. DOI: https://doi.org/10.18632/oncotarget.13854

49. Matsumoto A., Hieda M., Yokoyama Y., et al. Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Med. 2015; 4: 1547–57. DOI: https://doi.org/10.1002/cam4.495

50. Liu J., Zhang Y., Li Q., Wang Y. Transgelins: cytoskeletal associated proteins implicated in the metastasis of colorectal cancer. Front Cell Dev Biol. 2020; 8: 573859. DOI: https://doi.org/10.3389/fcell.2020.573859

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)